Mala Srivastava

Learn More
BACKGROUND AIMS A phase II clinical trial of an autologous dendritic cell (DC) formulation for the management of refractory solid malignant tumors was conducted across six sites in India with an objective to study safety and efficacy. METHODS A total of 51 patients with refractory cancer (either sex) with life expectancy ≥3 months, Eastern Cooperative(More)
  • 1